Search Results
Your search for all items matches 37071 pages
Showing 1 - 50Presidential Symposium Highlights in Small Cell Lung Cancer
Three phase III studies in small cell lung cancer (SCLC) were among the notable findings presented during a Presidential Symposium at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer held in Seoul. The studies addressed important questions...
Real-World Data Are Not Necessarily Real-World Evidence
Real-world data (RWD) provide raw material from which real-world evidence (RWE) is generated, but the two terms are not synonymous. Over the past decade, RWD and RWE have become increasingly prominent in oncology. A search of the 2016 ASCO Annual Meeting abstracts identified 48 with terms “real...
FDA Grants Traditional Approval to Pembrolizumab for TMB-H Solid Tumors
On October 16, 2026, the U.S. Food and Drug Administration (FDA) granted traditional approval to pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden–high...
Of Note in the Oncology Community: September/October 2026
Areej R. El-Jawahri, MD, FASCO, was named by ASCO as the 2026 recipient of the Joseph Simone Quality Care Award. She accepted her award and presented her keynote lecture at the 2026 ASCO Quality Care Symposium held recently in Boston. Dr. El-Jawahri is Co-Director of the Cancer Outcomes Research...
Three Decades of AYA Cancer Survivorship
Growing up, I was a curious, empathetic kid with an interest in biology. When I was diagnosed with non-Hodgkin lymphoma 2 months before I turned 15, those qualities shaped how I engaged with my care. I asked questions, wanted to understand what was happening in my body, and built strong...
Robert A. Kyle, MD, Renowned Expert in Myeloma, Dies at 98
The International Myeloma Foundation (IMF) shared news on the passing of Robert A. Kyle, MD, at age 98 on September 2, 2026. Dr. Kyle was a highly-revered expert in the field of myeloma research and known to many as the “Father of Myeloma” for his groundbreaking work in hematology. Dr. Kyle was...
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab in Mycosis Fungoides and Sézary Syndrome
The final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides and Sézary syndrome were recently presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting 2026 in Berlin, Germany...
Mammography Screening for Recurrence After a Diagnosis of Breast Cancer
Nahleh and colleagues recently updated ASCO guidelines regarding the frequency of breast screening following a diagnosis of primary breast cancer and recommended annual mammography for most patients.1 Presumably, the benefit of mammography will come from finding recurrences earlier, e.g., smaller...
Financial Incentives Increase Smoking Abstinence Among Those Referred for Lung Cancer Screening
Among medically underserved adults who smoked and were referred for lung cancer screening, the addition of financial incentives to usual care and free pharmacotherapy significantly increased rates of sustained tobacco abstinence compared with usual care alone or usual care plus free...
Patient-Friendly Research Summaries Spotlight Advances in Pancreatic Cancer
The science and practice of translation is about more than moving discoveries from the lab to the clinic. It also helps break down barriers to access so crucial developments in cancer care can reach patients and improve outcomes all over the world. To help you spread the word about these...
ASCO Issues Its First Living Guideline on Systemic Treatment of Recurrent Ovarian Cancer
In June 2026, an ASCO Expert Panel voted to approve ASCO’s first Living Guideline on systemic treatment of ovarian cancer recurrence.1 The continuously updated, evidence-based guideline addresses patients with epithelial ovarian cancer, primary peritoneal carcinoma, and fallopian tube carcinoma,...
Geographic Distribution of Triple-Negative Breast Cancer Clinical Trials
A recent study by researchers from The Univetsity of Texas MD Anderson Cancer Center, ASCO, and collaborating institutions evaluated the national landscape of geographic access to active triple-negative breast cancer clinical trials. The findings—published by Amin et al in Breast Cancer Research...
Data From Pivotal Trials Lead to Recent Drug Approvals in Colorectal, Breast, RCC, and CLL/SLL Malignancies
In September and October, the U.S. Food and Drug Administration (FDA) released statements regarding the Agency’s approval of a number of oncology drug products across several solid tumors and hematologic malignancies. A summary of these approvals is provided here. Combination Approved in dMMR Colon ...
Metastasis-Directed Ablation Does Not Improve Survival Outcomes in Oligometastatic Breast Cancer
The addition of metastasis-directed ablation to first-line systemic therapy did not significantly improve progression-free or overall survival in patients with oligometastatic breast cancer, according to findings from the randomized phase II portion of the NRG-BR002 trial reported by Chmura et al...
Remote Expert Case Reviews Identify Opportunities to Improve Cancer Care and Reduce Costs
Remote expert review of oncology cases may help to address and improve gaps in evidence-based cancer care, while also providing measurable cost savings, according to findings presented in a poster at the 2026 ASCO Quality Care Symposium (Abstract 700). “Last year at ASCO's Quality Care Symposium,...
Phase III RT CHARM Trial Supports Shorter Postmastectomy Radiation Therapy After Breast Reconstruction
A shorter course of postmastectomy radiation therapy was noninferior to conventional radiation therapy in terms of breast reconstruction complications among women with breast cancer undergoing the procedure, according to findings from the randomized RT CHARM trial reported by Poppe et al in the...
Experts Call for Better Quality-of-Life Reporting in Adjuvant Cancer Trials
Clinical trials of adjuvant cancer therapy should do a better job of showing how treatment affects individual patients’ quality of life—particularly when the survival benefit is modest—according to recommendations from Common-Sense Oncology and the European Organisation for Research and Treatment...
Bivalent CAR T-Cell Therapy Shows Shows Durable Activity and Manageable Safety in Recurrent Glioblastoma
Longer follow-up from a phase I trial of intracerebroventricular bivalent CAR T-cell therapy in recurrent glioblastoma showed no long-term or delayed-onset toxicities, with a median overall survival of 12.0 months, according to updated data presented at the 2026 ASCO Annual Meeting.1 The...
Claudia Henschke, PhD, MD: Finding Lung Cancer in Time
I have had many idols in medicine. Many eventually let me down. Claudia Henschke, PhD, MD, Professor of Radiology and Head of the Lung and Cardiac Screening Program at Mount Sinai Medical Center in New York City, an expert in diagnostic radiology, and a pioneer in computed tomography (CT) screening ...
AI Model Based on Facial Image Analysis Estimates Biological Age and Mortality Risk in Patients With Cancer
Analyzing facial images using a foundational artificial intelligence (AI) model may help researchers determine both biological aging and disease-related mortality risk, according to study findings published in The Lancet Digital Health. “As the population ages, physicians need better ways to...
Evolving Strategies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
When diffuse large B-cell lymphoma (DLBCL) fails to respond to front-line treatment or the disease later returns, Jeremy S. Abramson, MD, MMSc, wants to know when the disease progressed, if the patient is eligible for chimeric antigen receptor (CAR) T-cell therapy, and whether or not such treatment ...
Community Oncology Practices Bring Advances in Cancer Testing and Treatment Closer to Patients
Community oncology practices are bringing personalized medicine into everyday cancer care, substantially expanding their use of advanced biomarker testing and novel therapies for patients with metastatic breast cancer and metastatic non–small cell lung cancer, according to new research from...
FDA Approves Dostarlimab for MSI-H/dMMR Locally Advanced Rectal Cancer
On October 19, 2026, the U.S. Food and Drug Administration (FDA) granted an accelerated approval to the PD-1 inhibitor dostarlimab (Jemperli) for the treatment of adult patients with stage II/III locally advanced rectal cancer that is microsatellite instability–high (MSI-H) or mismatch repair...
Mocertatug Rezetecan Shows Early Activity in Platinum-Resistant Ovarian and Endometrial Cancers
First results from the global phase I BEHOLD-1 study suggest that the investigational B7-H4–targeted antibody-drug conjugate mocertatug rezetecan showed activity in two difficult-to-treat gynecologic cancers: platinum-resistant ovarian cancer and recurrent or advanced endometrial cancer.1 At the...
ASH Issues New Recommendations for the Management of Myelofibrosis
The American Society of Hematology (ASH) released new guidelines on the management of myelofibrosis which recommend expanded molecular testing, early transplant referral, appropriate use of JAK inhibitors, and aspirin therapy in select patients. The guidelines were published by Stein et al in Blood ...
Immunotherapy-Based Downstaging Linked to Improved Outcomes After Liver Transplantation in Hepatocellular Carcinoma
An immune checkpoint inhibitor–based multimodal downstaging strategy before liver transplantation was associated with improved posttransplant survival and a lower risk of recurrence among patients with hepatocellular carcinoma initially beyond the Milan criteria (single lesion not larger than 5 cm...
Novel Androgen Receptor Degrader Demonstrates Antitumor Activity in Advanced Prostate Cancer
The novel androgen receptor degrader bavdegalutamide demonstrated a manageable safety profile and antitumor activity in patients with metastatic castration–resistant prostate cancer previously treated with androgen receptor pathway inhibitors, particularly those with tumors harboring specific...
Phase III VERIFY Trial Demonstrates Benefits of Rusfertide in Polycythemia Vera
According to findings from the phase III VERIFY trial reported by Kuykendall et al in the Journal of Clinical Oncology, the addition of the hepcidin mimetic rusfertide to standard-of-care therapy significantly improved hematocrit control, reduced the need for phlebotomy, and improved...
Even Highly Curable Childhood Leukemias Take a Substantial Toll on Families, Study Finds
New research published by Rodwin et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that families of children receiving treatment for B-cell acute lymphoblastic leukemia (ALL) experience substantial and lasting challenges beginning early after diagnosis, according to a...
Iberdomide Triplet Improves MRD-Negative Complete Response in Relapsed/Refractory Multiple Myeloma
Iberdomide combined with daratumumab and dexamethasone nearly doubled the rate of minimal residual disease (MRD)-negative complete response compared with daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma. Lonial et al reported the primary MRD...
ASCO 2026: Lung Cancer Specialist Apar Kishor Ganti, MD, Shares His Insights
The 2026 ASCO Annual Meeting featured numerous high-impact studies in lung cancer. To help readers identify the presentations with the greatest potential to influence clinical practice, The ASCO Post asked lung cancer specialist Apar Kishor Ganti, MD, MS, FASCO, to share his top picks. Dr. Ganti is ...
Two Studies Show Breast Cancer Survival and Mortality Gaps Are Widening Between Rural and Urban Areas
Survival and mortality disparities for women with breast cancer are widening between rural and urban areas over time, according to findings from two American Cancer Society studies presented at the 2026 ASCO Quality Care Symposium (Abstracts 208 and 253). The studies found that women from rural...
Amyloidosis: Novel Treatments Could Improve Poor Outcomes
Systemic light chain amyloidosis is a clonal plasma cell disorder that can lead to end-organ dysfunction, with no approved treatment in the relapsed/refractory setting. Given this challenging clinical situation, two studies of novel therapies for this disease reported at the 2026 ASCO Annual...
Chronic Immune-Related Adverse Events Common After Adjuvant Anti–PD-1 Therapy for Melanoma
Nearly half of patients with resected high-risk melanoma treated with adjuvant anti–PD-1 therapy developed chronic immune-related adverse events, and more than one-third still had ongoing toxicity after a median follow-up of more than 5 years. Roma A. Kankaria, MD, and colleagues reported the...
ASCO and WHO Formalize Partnership
Cancer is one of the leading causes of morbidity and mortality worldwide, affecting 92% of families around the world, according to the latest estimates from the World Health Organization (WHO) Global status report on cancer 2026. The highest health, social, and economic burdens occur in low- and...
Study Supports Universal Germline Genetic Testing Regardless of Age at Cancer Diagnosis
Universal germline genetic testing after an individual receives a cancer diagnosis may help to uncover hereditary cancer risks in the patient's family, according to findings published in Cancer Discovery. In a study of a pan–solid tumor cohort, researchers found enriched germline pathogenic...
FDA Approves Expanded Indication for Nogapendekin Alfa Inbakicept in BCG-Unresponsive NMIBC
On October 14, 2026, the U.S. Food and Drug Administration (FDA) approved the IL-15 receptor agonist nogapendekin alfa inbakicept-pmln (Anktiva) in combination with bacillus Calmette-Guérin (BCG) for the treatment of adults with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC). This...
Facilitated Cascade Genetic Testing Improves Uptake Among Relatives of BRCA1/2 Variant Carriers
According to findings from a randomized controlled trial reported by Wilke et al in the Journal of Clinical Oncology, a clinician-facilitated approach to cascade genetic testing significantly increased genetic testing uptake among first-degree relatives of individuals with BRCA1 or BRCA2 pathogenic ...
Sitagliptin Added to Standard Prophylaxis Reduces Risk of Acute GVHD Following Alternative Donor Transplantation
Adding the selective, oral dipeptidyl peptidase-4 inhibitor, sitagliptin, to antithymocyte globulin–based prophylaxis significantly reduced the incidence of grade 2 to 4 acute graft-vs-host disease (GVHD) among patients undergoing alternative donor hematopoietic stem-cell transplantation, according ...
Automated vs Handheld Ultrasound for Breast Cancer Screening
A new study by Rauscher et al in the Journal of the American College of Radiology has found that automated breast ultrasound (ABUS) and handheld ultrasound (HHUS) had similar cancer detection rates in women with dense breasts, whereas ABUS had a lower false-positive rate. These data demonstrate...
ASCO Remembers Dr. Rachna T. Shroff, Expert in Gastrointestinal Cancers and Dedicated ASCO Volunteer
ASCO joins the oncology community in mourning the death of Rachna T. Shroff, MD, MS, FASCO, a renowned expert specializing in gastrointestinal (GI) cancers and a dedicated ASCO volunteer. Dr. Shroff passed away following a battle with an aggressive cancer. After completing her training, Dr....
Implementing Massage and Acupuncture to Achieve Better Pain Management in Oncology Care: An Overview of the IMAGINE Project
Pain is an incredibly challenging symptom that affects over 40% of patients with cancer in active treatment1 and up to two in three patients with advanced cancer.2 Analgesic pain medications including opioids have been the predominant pain management strategy; however, their use is limited by...
Anitocabtagene Autoleucel Shows High Response Rate in Heavily Pretreated Relapsed/Refractory Multiple Myeloma
Anitocabtagene autoleucel (anito-cel), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, produced responses in all treated patients in a phase I study of heavily pretreated relapsed or refractory multiple myeloma, with 79% achieving a...
Remote Exercise Program Reduces Cancer-Related Fatigue, Improves Quality of Life for Patients Undergoing Immunotherapy
A supervised remote exercise program improved the quality of life of patients with cancer undergoing immunotherapy, primarily by reducing cancer fatigue, according to findings from a secondary analysis of a phase II trial that will be presented at the 2026 ASCO Quality Care Symposium (Abstract...
Financial Navigation Support May Help Reduce Financial Toxicity for Some People With Advanced Cancer
Results from the randomized nationwide CREDIT trial showed that a financial navigation support program does not broadly reduce financial hardship for people being treated for advanced cancer. However, it can help a subgroup of people: those with existing financial and social resources that make...
The Wistar Institute Names New President and Chief Executive Officer
The Wistar Institute’s Board of Trustees has appointed Ronny Drapkin, MD, PhD, a physician-scientist and ovarian cancer researcher at the University of Pennsylvania Perelman School of Medicine, to be the Institute’s next President and Chief Executive Officer, effective November 30, 2026. Dr....
Early Research Links Abdominal Obesity to Increased Lung Cancer Risk
Findings from a recent study published in the Journal of Thoracic Oncology challenge the idea that an obesity paradox contributes to reduced lung cancer risk—instead, the data suggested that obesity may be associated with enhanced lung carcinogenesis. “Overall, our data clearly associate central ...
HER2-Negative Advanced Gastric Cancers: First-Line Retlirafusp Alfa Combination Demonstrates Survival Benefit
The addition of retlirafusp alfa to capecitabine and oxaliplatin (CAPOX) significantly prolonged overall survival compared with chemotherapy alone as first-line treatment for patients with unresectable, locally advanced or metastatic, HER2-negative gastric or gastroesophageal junction...
Study Identifies Insurance and Cost Barriers to Oral Therapies for Blood Cancers
A nationwide study of patients with blood cancers found that most prescriptions for specialty oral anticancer medications were initially rejected by insurers, and many patients did not fill their prescriptions even after receiving approval. The findings, reported by Doshi et al in the Journal of...
Neil M. Iyengar, MD, on Co-Occurring Mutations in Advanced Breast Cancer: Management Strategies
In hormone receptor–positive, HER2-negative metastatic breast cancer, co-occurring ESR1 and PIK3CA mutations create therapeutic complexity. Oral SERDs, including elacestrant, retain activity despite PIK3CA co-mutation and may offer an efficacy–toxicity balance compared with PI3K/AKT pathway...
